Sun. Jan 23rd, 2022

Like Pfizer, its American peer and equal, the Boston-based biotech company has actually jacked up the rate of its jabs as countries race to buy booster shots for next year. “There were ten years, over $2 billion of investment and hundreds of researchers working for many years to make all this possible.” Afeyan spoke to The Sunday Times as Moderna felt the sharp end of a dispute over vaccine rates.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Wizadclick | WAC MAG 2022